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Summary.
 
The evasion and subversion of immune
 
responses during infection has elucidated many interesting
and ingenious pathways used by pathogens to survive,
 
expand, and eventually be transmitted to new hosts. These
immune evasion mechanisms are of interest as they frequently
suggest ways to prevent pathogens from causing infection or
disease. More rarely, they make us consider or evaluate the
whole strategy of vaccine or disease prevention.
The 
 
Plasmodium 
 
species that cause malaria have classical
immune evasion strategies through apparently immuno-
logically distinct replication cycles and sites with the host
and polymorphic and clonally variant antigens (1, 2).
Recently,  the human parasite 
 
Plasmodium falciparum 
 
was
shown to modulate host defences more directly by altering
the function of antigen-presenting cells (3, 4). The paper in
this issue by Ocaña-Morgner et al. (5) describing inhibition
 
of CD8
 
  
 
T cell responses during murine malaria infection
extends these observations and not only suggests a novel
scheme of immune subversion by the parasite, but also
poses important questions for the existing strategies to
develop a vaccine against malaria.
 
Dendritic Cells (DCs).
 
The role of DCs in orchestrating
immune responses has become apparent in recent years and
is encapsulated in their subtitle of professional antigen-
presenting  cells (for review see reference 6). Subtypes of
myeloid, plasmacytotoid, and Langerhans DCs appear to
have some different functions in different tissues or sites.
Nevertheless, a common feature of DCs is their ability to
phagocytose antigens, undergo a process of maturation in
response to exogenous or endogenous signals, and up-
regulate the requisite molecules to stimulate lymphocytes
including memory and naive T, B, and NK cells. Myeloid
DCs in humans can activate CD4
 
  
 
T cells to proliferate and
secrete Th1- or Th2-type cytokines and also cross-present
 
exogenous antigens to cytotoxic CD8
 
  
 
T cells. Given the
pivotal role of DCs in the stimulation of innate and acquired
immune responses, it is reasonable to suggest that these
cells play a significant role in the host’s defense against
 
P. falciparum
 
 malaria.
 
Malaria.
 
Most morbidity and mortality from malaria is
 
caused by infection with 
 
P. falciparum
 
. Falciparum malaria is
not simply a major public health problem but it is even con-
sidered to restrain economic growth in many parts of the
world (7). The mainstay of disease control is the detection and
treatment of cases. However, the rise of drug-resistant parasites
and the cost of effective therapy have made the development
of a simple, cheap, and effective vaccine imperative.
The life cycle of the parasite appears complex but in essence
has a liver phase of preamplification of a few to many thousand
of infective forms in hepatocytes. This obligatory phase
liver stage is the prelude to logarithmic growth in the blood
as parasites enter and multiply within erythrocytes. The
blood parasitemia might be substantial and accompanied by
severe clinical symptoms including coma, metabolic acidosis
and signs of severe anemia in children, and multisystem
failure in nonimmune adults (Fig. 1; reference 8).
Specific host effector responses against the falciparum
parasites appear to be distinct for liver and blood stage
parasites. There is substantial evidence that cytotoxic
lymphocytes can recognize and destroy intrahepatic parasites
 
(9, 10). More importantly, the secretion of IFN-
 
  
 
by both
CD4
 
  
 
and CD8
 
  
 
T cells has been associated with protective
immune responses (9, 11–13). Indirect evidence for the
presence of effective clinical immunity against liver stage
parasites includes the association of specific class I allotypes
with protection from malaria in a large case-control study
in the Gambia (14) and the frequency of nonsynonymous
to synonymous base substitution in the coding sequences
for liver stage antigens circumsporozoite protein, liver
stage antigen 1, and thrombospondin-related anonymous
protein. (15–17).
Specific immunity against blood stage antigens includes
antibodies directed against parasite molecules required for
invasion of erythrocytes and antibodies able to stimulate
antibody-dependent cytotoxicity (18, 19). Other antibodies
recognizing the adhesive and variant proteins (P. falciparum
membrane protein 1 [PfEMP-1]) expressed on the surface
 
Address correspondence to David J. Roberts, National Blood Service-
Oxford, John Radcliffe Hospital, Level 2, Headington, Oxford OX3
9DU, United Kingdom. Phone: 44-186-522-0559; Fax: 44-1865-
467957; E-mail: david.roberts@ndcls.ox.ac.uk 
138
 
Commentary
 
of erythrocytes may inhibit adhesion of infected erythro-
cytes to host ligands and/or enhance their phagocytosis of
infected erythrocytes (Fig. 1; references 20 and 21).
 
Malaria Vaccines.
 
Several strategies are being followed
to develop a vaccine against 
 
P. falciparum
 
 and are aimed at
the liver stage, blood stage, and at “toxins” (including
the malaria-specific glycosylphosphatidyl-inositol linkage)
that may provoke host cell damage. Blood stage and anti-
toxin vaccine programs have identified several potential
candidate antigens that are being evaluated in animal
models of malaria (22, 23).
Although there is ample evidence for the presence of
anti-liver stage immune responses in individuals living in
endemic areas, these effector mechanisms are not capable
of complete elimination of parasites as people continue to
suffer from successful liver stage infection and thus blood
stage infection throughout their lives. Ongoing attempts
to develop vaccines are focusing on the induction of cel-
lular responses against the liver stage of the parasite based
on the observation that potent protection against liver
stages was achieved by inoculation with irradiated but not
live sporozoites (24, 25).
Figure 1. The life cycle of falci-
parum malaria Sporozoites, from
female  Anopheles mosquitoes
taking a blood meal, enter the
circulation and invade hepato-
cytes.   10,000 merozoites are
formed by days 10–14. After rup-
ture of the hepatocyte, the infec-
tive merozoites are released and
invade erythrocytes. Here, the
blood stage parasites can multi-
ply approximately eightfold every
2 d and therefore within a short
time a high proportion of erythro-
cytes might be infected compris-
ing up to several grams of foreign
antigens. During the second
half of the erythrocytic cycle,
PfEMP-1 or the variant antigen is
expressed on the surface of in-
fected erythrocytes. This family of
proteins, and maybe other adhe-
sive proteins, mediate the adhe-
sion of infected erythrocytes to
host receptors on endothelium, un-
infected erythrocytes, and platelets
(for reviews see references 38 and
39). Asexual parasites may differ-
entiate into sexual forms or game-
tocytes.  The parasite life cycle is
completed within the female
Anopheles mosquito after the
sexual forms of the parasite are
ingested in a blood meal. Immune
responses against the plasmodium
parasites are distinct for liver and
blood stage parasites. Cytotoxic
lymphocytes can recognize and
destroy intrahepatic parasites and
secretion of IFN-  by both CD4 
and CD8  T cells is associated with
protective immune responses.
Specific immunity against blood
stage antigens includes antibodies
directed against parasite mole-
cules required for invasion of
erythrocytes and antibodies recog-
nizing the adhesive and variant
proteins (PfEMP-1) expressed on
the surface of erythrocytes. In-
fected erythrocytes may also be phagocytosed by splenic macrophages and/or destroyed by antibody-dependent cytotoxicity. Other effector mechanisms
are poorly defined. Immune responses might be subverted during the blood stage of infection. (A) In this issue, Ocaña-Morgner et al. (reference 5) de-
scribe the inhibition of CD8  T cell responses during murine malaria infection. (B) Adhesion of infected erythrocytes to DCs via CD36 and CD51 ( v in-
tegrin of the  v 3 or  v 5 heterodimer) may modulate DC function. These interactions reduce the ability of myeloid DCs to stimulate primary and second-
ary CD4  T cell responses (references 3 and 4). (C) Adhesion of infected erythrocytes to macrophages may reduce secretion of inflammatory cytokines
including TNF-  (reference 40). 
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It is hoped that strong cellular responses can be induced
against liver stage antigens to destroy a proportion of the
parasites developing within hepatocytes so that the num-
ber of parasites entering the blood would be reduced (for
reviews see references 26 and 27). This would increase
the time for a clinically significant parasitemia to develop
and might allow the defences against blood stage parasites
to be more effective.
 
New Evidence of Inhibition of Liver Stage Responses by Ma-
laria Parasites.
 
The data provided by Ocaña-Morgner et
al. (5) in this issue now provide an explanation for the dis-
crepancy in the immunogenicity of live and irradiated
sporozoites and indeed natural exposure to liver stages of
 
Plasmodium
 
. Using a rodent model of malaria, they present
compelling evidence for the modulation of myeloid DCs
during blood stage 
 
Plasmodium yoelii
 
 infection resulting in
the inhibition of CD8
 
  
 
T cell responses.
First, they show that irradiated sporozoites of 
 
P. yoelii
 
 in
BALB/c mice induce a CD8
 
  
 
T cell response against an
epitope of the circumsporozoite protein strongly expressed on
the sporozoite surface. This CD8
 
  
 
T cell response is abrogated
either by the simultaneous injection of viable nonirradiated
sporozoites that go on to develop blood stage infection or
by direct inoculation of blood stage forms themselves. The
inhibitory effect of nonirradiated sporozoites is abolished
by chemotherapy directed at blood stage parasites. Second,
they show that the presence of low levels of 
 
P. yoelii
 
–infected
erythrocytes suppress the priming of CD8
 
  
 
T cell responses
normally induced by irradiated sporozoites.
It appears that inhibition of CD8
 
  
 
T cell responses is
mediated by DCs. Ocaña-Morgner et al. go on to show
that maturation of bone marrow–derived DCs in vitro
and ex vivo is inhibited and the survival of the DCs in
vitro is increased after their exposure to blood stage para-
sites. Furthermore, after exposure to blood stage parasites
the pattern of cytokine secretion by DCs is profoundly
modified. IL-12 secretion is reduced and Il-10 secretion
increased in response to LPS. Finally, after exposure to
blood stage parasites either in vivo or in vivo, DCs fail to
activate a CD8
 
  
 
T cell clone. Thus, isolated live sporozoites
do not inhibit DCs directly.
Their findings are consistent with the observations made
with 
 
P. falciparum
 
 parasites in vitro where myeloid DCs
were modulated by the adhesion of infection erythrocytes
(3). Here, there was good evidence that CD4
 
  
 
T cells were
rendered functionally unresponsive and although adhesion
of infected erythrocytes to DCs increased IL-10 secretion,
inhibition of primary and recall CD4
 
  
 
T cells was not
obviously mediated by this cytokine (4).
By contrast, modulation of DC function was not ob-
served with erythrocytes infected with the rodent para-
site 
 
Plasmodium chabaudi
 
 
 
chabaudi
 
 (28). Here, bone mar-
row–derived DCs produce TNF-
 
 
 
, IFN-
 
 
 
, and IL-12
and mature normally in response to LPS when exposed
to the parasite although their ability to support T cell ac-
tivation was not investigated. Although another group
also observed normal DC maturation in response to 
 
P.
 
yoelii
 
–infected erythrocytes, they nevertheless established
that these DCs inhibited T cell proliferation and IL-2
secretion (29).
The data from Ocaña-Morgner et al. support the suggestion
that the ability of parasites to modulate the function of
immune system of their vertebrate host is not a singular fea-
ture of 
 
P. falciparum
 
, but a more general feature of 
 
Plasmodium
spp
 
 (3, 30). The precise mechanism involving cytoadhesion or
soluble factors, or indeed both, may vary between parasite
strains that have adopted to their particular host. These mech-
anism(s), including cytoadhesion, may simply serve to protect
the more vulnerable stages of the parasitic life cycle, i.e.,
sporozoites and gametocytes.
Clearly, the suppression of liver stage immune responses
has to be confirmed in humans. The epidemiology of the
disease, with the failure of natural immunity to liver stage
to prevent continued reinfection even in the most heavily
exposed individuals, suggests immunity to the liver stage
cannot provide sterile immunity. Indeed, direct observa-
tion of CD8
 
  
 
T cell responses during malaria infection in
endemic areas exposed to malaria parasites have yielded
lower responses than might be expected (31). Previous ex-
planations for the ability of fresh infection to establish and
flourish the liver would have included polymorphic T cell
epitopes, T cell antagonism by altered peptide ligands, and
stochastic events allowing a few parasites to evade and escape
detection (32). However, active suppression of immunity
to liver stage parasites during blood stage infection adds
a new dimension to the dynamics of parasite survival
within the host.
 
Regulation of CD8
 
  
 
T Cell Responses During Malaria Infec-
tion.
 
The suppression of CD8
 
  
 
T cell responses during
blood stage infection has wider consequences for the immune
response not only to malaria but also to other infectious
agents. Indeed, the suppression of CD8
 
  
 
T cell responses is
consistent with the association of Burkitt’s lymphoma and
endemic malaria (33). It has been suggested that malaria
must induce loss of control of EBV-infected B lymphocytes
(34) or provide a mitogen or mechanism that stimulates B
cell growth (35). The observations by Ocaña-Morgner et
al. suggest a mechanism for the failure of CD8
 
  
 
lympho-
cytes to control EBV-infected lymphocytes.
The dysregulation of CD8
 
  
 
T cells as a result of malaria
infection might be even more extensive. Suppression of
specific CD8
 
  
 
T cell responses during blood stage malaria
may explain the higher viral load in HIV
 
  
 
individuals not
only during but after infection with 
 
P. falciparum
 
 (36).
There is the potential for malaria infection to accelerate the
progression of HIV, although a recent systematic review of
the area suggested that there is no convincing evidence for
an interaction between malaria and HIV with the possible
exception of an interaction between placental malaria and
HIV infection (37). The overall significance of CD8
 
  
 
T
cell suppression during 
 
P. falciparum
 
 infection will clearly
require study in the clinic and the laboratory and may have
far reaching consequences for the implementation of public
health measures. 
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Regulation of CD8
 
  
 
T Cell Responses and Vaccine Develop-
ment.
 
What would the implications be for vaccine develop-
ment for malaria if these or functionally similar mechanisms of
CD8
 
  
 
T cell dysregulation occurred in human infection?
There has been an unspoken assumption that immunity to
liver and blood stage parasites are independent. However, we
may not be able to regard these apparently distinct immune
responses in isolation in natural infection.
For example, we now have to consider that the T cell
responses might be reduced as a result of patent blood stage
infection. One immediate implication that the levels of T
cell responses measured during a clinical infection may not
necessarily indicate the level of those responses before
infection. Thus, the association between T cell responses
and clinical protection could only reliably be established by
prospective studies.
Of more pressing concern is the finding by Ocaña-Morgner
et al. that blood stage parasites can inhibit established
CD8
 
  
 
T cell responses against liver stage parasites. If this
also occurs in human infection in endemic areas, then the
effectiveness of any liver stage vaccine would be less than
that expected by challenge studies where significant blood
stage infections do not develop. Vaccine development is
somewhat empirical even with ample preliminary data and
it might be that such concerns are unfounded by virtue of
the innate difference between mice and men or by the im-
mune responses induced by specific vaccination protocols.
On a more positive note, the interdependence of immunity
to liver and blood stages suggests that there might be synergy
between the control of parasite multiplication in the liver and
the blood. Thus, vaccines stimulating the appropriate immune
responses against liver or blood stage antigens or epitopes, and
giving partial protection against the respective stages, may have
a greater than additive effect when given together.
Of course it is “too early to tell” the significance of inhibi-
tion of CD8
 
  
 
T cell responses by malaria infection. At the
very least, the studies by Ocaña-Morgner et al. will stimulate
thought and experiment not only in malaria but also in many
areas of immunology. The results of these studies may
influence the strategies to develop malaria vaccines.
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